LB Pharmaceuticals appointed Joseph M. Miller as chief financial officer effective September 2, with an option to purchase 200,000 common shares. Investors receive defined compensation terms, including a $530,000 annual base salary and 40% target bonus, while the prospectus warns that investing in the securities involves a high degree of risk.

Key Highlights

  • Joseph M. Miller’s initial annual base salary is $530,000, with a discretionary Bonus target equal to 40% of annual base salary.
  • Miller most recently served as chief financial officer of Aurinia Pharmaceuticals and previously held senior finance roles at Avalo Therapeutics and Sucampo Pharmaceuticals.
  • The Equity award will be granted outside the 2025 Equity Incentive Plan while remaining subject to its terms.

The award will vest over four years, beginning with 25% on the first anniversary and continuing monthly afterward, subject to continued service.

$530,000 Salary and 40% Bonus Target

His employment is at will, and he may participate in employee benefit plans available generally to LB Pharmaceuticals (NASDAQ: LBRX) employees. The agreement also includes confidentiality obligations and a non-solicitation covenant. Miller is a certified public Accountant who earned an accounting degree from Villanova University and began his career in KPMG’s audit practice.

Change-of-Control Protection Covers Equity

The option is intended as an inducement for Miller to join LB Pharmaceuticals under Nasdaq Listing Rule 5635. If he is dismissed without cause or resigns for good reason during the specified change-of-control period, the agreement provides for salary based on the annual amount then in effect, 150% of the target bonus, COBRA reimbursement and acceleration of unvested equity awards. Other termination scenarios provide salary continuation and COBRA reimbursement. The last reported sale price of LB Pharmaceuticals common stock was $49.48 per share on September 2, 2026. Investing in the securities involves a high degree of risk.